Clinical risk factors for adverse events in allopurinol users

Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2013, Pages 211-216

  Ryu, Hee Jung ^a   Song, Ran ^a   Kim, Hye Won ^a   Kim, Jin Hyun ^a   Lee, Eun Young ^a   Lee, Yun Jong ^a   Song, Yeong Wook ^a   Lee, Eun Bong ^a  

^a Seoul National University   (South Korea)

Author keywords

Adverse events; Allopurinol; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; COLCHICINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRESS SYNDROME; DRUG USE; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GOUT; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; RASH; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR LYSIS SYNDROME;

ADULT; AGED; ALLOPURINOL; COLCHICINE; DRUG TOXICITY; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERURICEMIA; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84877859118     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012439715     Document Type: Article

References (39)

1. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep . 2009;11:135-140.
2. George J, Struthers AD. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther . 2008;26:59-64.
3. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev . 2006;58:87-114.
4. Neogi T. Clinical practice: gout. N Engl J Med . 2011;364:443-452.
5. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother . 1993;27:337-343.
6. Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J . 1979;72:1361-1368.
7. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum . 1986;29:82-87.
8. Tausche AK, Aringer M, Schroeder HE, et al. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med . 2008;121:e3-e4.
9. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol . 2008;58:25-32.
10. Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol . 2009;29:633-638.
11. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med . 1995;333:1600-1607.
12. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial . 2007;20:391-395.
13. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med . 1984;76:47-56.
14. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A . 2005;102:4134-4139.
15. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics . 2008;9:1617-1622.
16. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics . 2008;18:99-107.
17. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol . 1979;1:365-374.
18. Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity: association with thiazides and prior renal compromise. Arch Intern Med . 1974;134:553-558.
19. Danan G, Benichou C. Causality assessment of adverse reactions to drugs, I: a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol . 1993;46:1323-1330.
20. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem . 2007;53:766-772.
21. Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics . 1976;58:259-263.
22. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ . 2005;331:623-624.
23. Terkeltaub RA. Clinical practice: gout. N Engl J Med . 2003;349: 1647-1655.
24. Schumacher HR Jr. The pathogenesis of gout. Cleve Clin J Med . 2008;75(suppl 5):S2-S4.
25. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev . 2000;173:89-97.
26. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature . 2003;425:516-521.
27. Shi Y, Galusha SA, Rock KL. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol . 2006;176:3905-3908.
28. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med . 1998;339:1349-1357.
29. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet . 2002;360:7-22.
30. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA . 1998;279:1615-1622.
31. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med . 1995;333:1301-1307.
32. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med . 2008;14:37-44.
33. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol . 2007;27:435-440.
34. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood . 2007;110:4588-4598.
35. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol . 2006;33:1646-1650.
36. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis . 2001;60:981-983.
37. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol . 2010;5:1388-1393.
38. Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol . 2008;19:1204-1211.
39. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol . 2008;19: 2407-2413.